Concepts (194)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Anticoagulants | 29 | 2021 | 9563 | 2.67 | Why? |
| Warfarin | 5 | 2020 | 402 | 2.49 | Why? |
| Thrombophilia | 7 | 2021 | 1935 | 1.99 | Why? |
| Heart-Assist Devices | 7 | 2020 | 812 | 1.94 | Why? |
| Venous Thromboembolism | 16 | 2021 | 4273 | 1.49 | Why? |
| Factor Xa | 2 | 2019 | 113 | 1.46 | Why? |
| Blood Coagulation Factors | 2 | 2020 | 223 | 1.36 | Why? |
| Vitamin K | 3 | 2019 | 263 | 1.34 | Why? |
| Factor Xa Inhibitors | 5 | 2019 | 490 | 1.33 | Why? |
| International Normalized Ratio | 5 | 2020 | 300 | 1.28 | Why? |
| Thromboembolism | 7 | 2021 | 2101 | 1.26 | Why? |
| Thrombosis | 9 | 2021 | 7504 | 1.11 | Why? |
| Pyridones | 3 | 2019 | 738 | 0.96 | Why? |
| Antidotes | 2 | 2019 | 46 | 0.95 | Why? |
| Heparin | 6 | 2021 | 2600 | 0.94 | Why? |
| Hirudins | 2 | 2017 | 75 | 0.84 | Why? |
| Dabigatran | 3 | 2018 | 204 | 0.83 | Why? |
| Recombinant Proteins | 4 | 2019 | 3786 | 0.83 | Why? |
| Hemorrhage | 5 | 2019 | 3013 | 0.80 | Why? |
| Venous Thrombosis | 4 | 2020 | 2739 | 0.80 | Why? |
| Vascular System Injuries | 1 | 2020 | 91 | 0.80 | Why? |
| Red-Cell Aplasia, Pure | 1 | 2018 | 3 | 0.79 | Why? |
| Designer Drugs | 1 | 2018 | 12 | 0.77 | Why? |
| Blood Group Incompatibility | 1 | 2018 | 44 | 0.76 | Why? |
| Benzamides | 2 | 2018 | 421 | 0.74 | Why? |
| Premedication | 1 | 2018 | 40 | 0.73 | Why? |
| Rivaroxaban | 2 | 2019 | 467 | 0.72 | Why? |
| Pyrazoles | 3 | 2019 | 1791 | 0.69 | Why? |
| Phenylthiohydantoin | 1 | 2017 | 87 | 0.67 | Why? |
| Nomograms | 3 | 2018 | 790 | 0.64 | Why? |
| Cannabinoids | 1 | 2018 | 134 | 0.63 | Why? |
| Prostate-Specific Antigen | 1 | 2017 | 213 | 0.63 | Why? |
| Myelodysplastic Syndromes | 1 | 2018 | 261 | 0.60 | Why? |
| Pulmonary Embolism | 5 | 2020 | 4775 | 0.55 | Why? |
| Vasculitis | 1 | 2021 | 691 | 0.55 | Why? |
| Blood Coagulation Tests | 2 | 2018 | 855 | 0.53 | Why? |
| Cardiomyopathy, Dilated | 1 | 2017 | 251 | 0.53 | Why? |
| beta-Alanine | 1 | 2013 | 20 | 0.52 | Why? |
| Purpura, Thrombotic Thrombocytopenic | 1 | 2018 | 284 | 0.52 | Why? |
| Blood Coagulation | 8 | 2021 | 2768 | 0.51 | Why? |
| Pyridines | 1 | 2018 | 680 | 0.48 | Why? |
| Decision Support Systems, Clinical | 1 | 2018 | 551 | 0.48 | Why? |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2018 | 526 | 0.47 | Why? |
| Vascular Diseases | 1 | 2020 | 846 | 0.45 | Why? |
| Heparin, Low-Molecular-Weight | 2 | 2019 | 1731 | 0.44 | Why? |
| Drug Monitoring | 1 | 2018 | 1408 | 0.41 | Why? |
| Benzimidazoles | 1 | 2013 | 275 | 0.40 | Why? |
| Fibrinolytic Agents | 3 | 2021 | 1702 | 0.39 | Why? |
| Peptide Fragments | 2 | 2017 | 2075 | 0.39 | Why? |
| ABO Blood-Group System | 1 | 2018 | 995 | 0.39 | Why? |
| Antibodies, Monoclonal | 2 | 2018 | 8041 | 0.38 | Why? |
| Partial Thromboplastin Time | 3 | 2020 | 436 | 0.37 | Why? |
| Hematopoietic Stem Cell Transplantation | 2 | 2018 | 2426 | 0.35 | Why? |
| Heart Transplantation | 1 | 2017 | 1293 | 0.31 | Why? |
| Recurrence | 4 | 2019 | 3675 | 0.30 | Why? |
| Hematologic Neoplasms | 1 | 2018 | 2105 | 0.28 | Why? |
| Fibrinogen | 2 | 2020 | 1048 | 0.27 | Why? |
| Antithrombins | 2 | 2018 | 353 | 0.27 | Why? |
| Drug Therapy, Combination | 1 | 2018 | 7268 | 0.27 | Why? |
| Administration, Oral | 4 | 2019 | 2340 | 0.26 | Why? |
| Humans | 50 | 2021 | 930598 | 0.25 | Why? |
| Body Weight | 2 | 2019 | 1074 | 0.24 | Why? |
| Immunologic Factors | 1 | 2018 | 4206 | 0.23 | Why? |
| Heart Ventricles | 3 | 2019 | 1139 | 0.22 | Why? |
| Fibrin Fibrinogen Degradation Products | 4 | 2020 | 5993 | 0.21 | Why? |
| Lung Neoplasms | 1 | 2018 | 3228 | 0.21 | Why? |
| Hermanski-Pudlak Syndrome | 1 | 2018 | 5 | 0.19 | Why? |
| ADP-ribosyl Cyclase 1 | 1 | 2018 | 96 | 0.19 | Why? |
| Consolidation Chemotherapy | 1 | 2018 | 41 | 0.18 | Why? |
| Asparaginase | 1 | 2018 | 26 | 0.18 | Why? |
| Antibodies, Monoclonal, Humanized | 2 | 2018 | 9335 | 0.18 | Why? |
| Prothrombin Time | 1 | 2020 | 434 | 0.18 | Why? |
| Epidemics | 1 | 2018 | 6407 | 0.18 | Why? |
| Drug and Narcotic Control | 1 | 2019 | 134 | 0.17 | Why? |
| Neoplasms | 4 | 2021 | 17251 | 0.17 | Why? |
| Induction Chemotherapy | 1 | 2018 | 149 | 0.16 | Why? |
| Illinois | 1 | 2018 | 468 | 0.16 | Why? |
| Postoperative Hemorrhage | 1 | 2018 | 183 | 0.16 | Why? |
| Intensive Care Units | 2 | 2021 | 29594 | 0.16 | Why? |
| Blood Coagulation Disorders | 2 | 2020 | 2040 | 0.16 | Why? |
| Fibrinolysis | 1 | 2021 | 521 | 0.16 | Why? |
| Female | 19 | 2021 | 380317 | 0.15 | Why? |
| Pregnancy Complications, Hematologic | 1 | 2017 | 114 | 0.15 | Why? |
| Transplantation, Homologous | 1 | 2018 | 757 | 0.15 | Why? |
| Medication Therapy Management | 1 | 2019 | 312 | 0.15 | Why? |
| Drug Costs | 1 | 2019 | 313 | 0.15 | Why? |
| Male | 19 | 2021 | 367725 | 0.15 | Why? |
| Aged | 13 | 2021 | 215776 | 0.15 | Why? |
| Chromatography, Liquid | 1 | 2018 | 640 | 0.14 | Why? |
| Practice Guidelines as Topic | 5 | 2019 | 15421 | 0.14 | Why? |
| Markov Chains | 1 | 2016 | 502 | 0.14 | Why? |
| Quality-Adjusted Life Years | 1 | 2016 | 511 | 0.13 | Why? |
| Leukocytes | 1 | 2021 | 1046 | 0.13 | Why? |
| Postoperative Care | 1 | 2019 | 755 | 0.13 | Why? |
| Antibodies, Antiphospholipid | 1 | 2018 | 519 | 0.13 | Why? |
| Computed Tomography Angiography | 2 | 2020 | 2153 | 0.13 | Why? |
| Enoxaparin | 1 | 2020 | 1064 | 0.12 | Why? |
| Gastrointestinal Hemorrhage | 1 | 2019 | 669 | 0.12 | Why? |
| Pneumonia, Viral | 5 | 2020 | 243684 | 0.12 | Why? |
| Nitriles | 1 | 2017 | 1053 | 0.12 | Why? |
| Tandem Mass Spectrometry | 1 | 2018 | 1031 | 0.12 | Why? |
| Disseminated Intravascular Coagulation | 1 | 2021 | 994 | 0.12 | Why? |
| Propensity Score | 1 | 2021 | 2690 | 0.12 | Why? |
| Coronavirus Infections | 5 | 2020 | 253789 | 0.12 | Why? |
| L-Lactate Dehydrogenase | 1 | 2020 | 1995 | 0.12 | Why? |
| Drug Hypersensitivity | 1 | 2018 | 401 | 0.12 | Why? |
| Antineoplastic Agents | 2 | 2018 | 3550 | 0.11 | Why? |
| Medicare | 1 | 2019 | 1048 | 0.11 | Why? |
| Middle Aged | 15 | 2021 | 270681 | 0.11 | Why? |
| Ferritins | 1 | 2020 | 2055 | 0.11 | Why? |
| Plasma Exchange | 1 | 2018 | 763 | 0.11 | Why? |
| Tissue Plasminogen Activator | 1 | 2017 | 778 | 0.11 | Why? |
| Drug Interactions | 1 | 2018 | 1653 | 0.11 | Why? |
| Algorithms | 2 | 2018 | 7346 | 0.10 | Why? |
| Rituximab | 1 | 2018 | 1096 | 0.10 | Why? |
| Intracranial Hemorrhages | 1 | 2018 | 1170 | 0.10 | Why? |
| Endothelium, Vascular | 1 | 2021 | 1751 | 0.10 | Why? |
| Disease Management | 2 | 2018 | 6841 | 0.10 | Why? |
| Patient Readmission | 1 | 2019 | 1543 | 0.10 | Why? |
| Clinical Trials as Topic | 2 | 2019 | 7330 | 0.10 | Why? |
| Lymphopenia | 1 | 2021 | 2669 | 0.09 | Why? |
| Academic Medical Centers | 2 | 2018 | 3088 | 0.09 | Why? |
| Pandemics | 6 | 2021 | 389249 | 0.09 | Why? |
| Adult | 8 | 2020 | 244371 | 0.08 | Why? |
| Incidence | 2 | 2020 | 25622 | 0.08 | Why? |
| Pregnancy | 2 | 2021 | 23879 | 0.08 | Why? |
| Cost-Benefit Analysis | 1 | 2016 | 2259 | 0.08 | Why? |
| Forecasting | 1 | 2021 | 4492 | 0.08 | Why? |
| Treatment Outcome | 5 | 2020 | 51732 | 0.08 | Why? |
| Lung Transplantation | 1 | 2018 | 1554 | 0.08 | Why? |
| Thrombolytic Therapy | 1 | 2017 | 2218 | 0.07 | Why? |
| Body Mass Index | 1 | 2019 | 4306 | 0.07 | Why? |
| Health Resources | 1 | 2019 | 2592 | 0.07 | Why? |
| Nurses | 2 | 2018 | 2285 | 0.07 | Why? |
| Aged, 80 and over | 4 | 2019 | 88759 | 0.07 | Why? |
| Guideline Adherence | 1 | 2018 | 2309 | 0.07 | Why? |
| Risk Factors | 6 | 2020 | 71621 | 0.07 | Why? |
| Neutrophils | 1 | 2021 | 5476 | 0.07 | Why? |
| Thrombocytopenia | 1 | 2017 | 2093 | 0.07 | Why? |
| Ultrasonography | 1 | 2020 | 4409 | 0.07 | Why? |
| C-Reactive Protein | 1 | 2020 | 7972 | 0.07 | Why? |
| Retrospective Studies | 5 | 2021 | 105322 | 0.06 | Why? |
| Risk Assessment | 3 | 2021 | 25439 | 0.06 | Why? |
| Ambulatory Care | 1 | 2018 | 4947 | 0.05 | Why? |
| Betacoronavirus | 5 | 2020 | 204454 | 0.05 | Why? |
| Patient Advocacy | 1 | 2021 | 173 | 0.05 | Why? |
| Case-Control Studies | 1 | 2018 | 17671 | 0.05 | Why? |
| Hospitalization | 2 | 2020 | 54280 | 0.05 | Why? |
| Vena Cava Filters | 1 | 2019 | 89 | 0.05 | Why? |
| Cholecystectomy, Laparoscopic | 1 | 2019 | 120 | 0.04 | Why? |
| Age Factors | 1 | 2019 | 21039 | 0.04 | Why? |
| Central Venous Catheters | 1 | 2019 | 188 | 0.04 | Why? |
| Biomarkers | 1 | 2020 | 23361 | 0.04 | Why? |
| Heart Failure | 1 | 2018 | 6638 | 0.04 | Why? |
| Syndrome | 1 | 2021 | 1310 | 0.04 | Why? |
| Pregnancy Complications, Infectious | 1 | 2021 | 11559 | 0.04 | Why? |
| Time Factors | 1 | 2019 | 31397 | 0.04 | Why? |
| Blood Cell Count | 1 | 2021 | 1101 | 0.04 | Why? |
| Drug Substitution | 1 | 2017 | 385 | 0.03 | Why? |
| Infusions, Intravenous | 1 | 2017 | 1224 | 0.03 | Why? |
| Lung | 1 | 2021 | 31049 | 0.03 | Why? |
| Severity of Illness Index | 1 | 2020 | 48226 | 0.03 | Why? |
| Prospective Studies | 1 | 2017 | 43301 | 0.03 | Why? |
| United States | 1 | 2019 | 46150 | 0.03 | Why? |
| Child | 1 | 2021 | 70012 | 0.03 | Why? |
| Leukocyte Count | 1 | 2021 | 3178 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2017 | 2324 | 0.03 | Why? |
| Adolescent | 2 | 2018 | 86841 | 0.03 | Why? |
| Disease Outbreaks | 1 | 2018 | 27595 | 0.03 | Why? |
| Nurse's Role | 1 | 2018 | 614 | 0.03 | Why? |
| Young Adult | 2 | 2018 | 93724 | 0.03 | Why? |
| Tertiary Care Centers | 2 | 2018 | 8248 | 0.02 | Why? |
| Dose-Response Relationship, Drug | 1 | 2018 | 3776 | 0.02 | Why? |
| Acute Disease | 1 | 2021 | 6029 | 0.02 | Why? |
| Pulmonary Fibrosis | 1 | 2018 | 1068 | 0.02 | Why? |
| Endoscopy, Gastrointestinal | 1 | 2019 | 1545 | 0.02 | Why? |
| Fatal Outcome | 1 | 2017 | 3438 | 0.02 | Why? |
| Autoantibodies | 1 | 2018 | 2094 | 0.02 | Why? |
| Clinical Decision-Making | 1 | 2020 | 3755 | 0.02 | Why? |
| Patient Selection | 1 | 2020 | 4560 | 0.02 | Why? |
| Acute Coronary Syndrome | 1 | 2018 | 2107 | 0.02 | Why? |
| Atrial Fibrillation | 1 | 2018 | 2320 | 0.02 | Why? |
| Disease Progression | 1 | 2021 | 13580 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2021 | 10649 | 0.01 | Why? |
| Postoperative Complications | 1 | 2019 | 5861 | 0.01 | Why? |
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 6653 | 0.01 | Why? |
| Immunoglobulin M | 1 | 2018 | 9091 | 0.01 | Why? |
| Host-Pathogen Interactions | 1 | 2020 | 11041 | 0.01 | Why? |
| Cohort Studies | 1 | 2021 | 36005 | 0.01 | Why? |
| Critical Illness | 1 | 2021 | 17281 | 0.01 | Why? |
| Cardiovascular Diseases | 1 | 2021 | 11497 | 0.01 | Why? |
| Stroke | 1 | 2018 | 8839 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2018 | 21571 | 0.01 | Why? |
| Tomography, X-Ray Computed | 1 | 2017 | 25144 | 0.01 | Why? |
Connors's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(194)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(150)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_